Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-NK
- Development stage
- Preclinical
- Lead developer
- NKGen Biotech, Inc.
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-NK (Atigen-Cell and Tissue Center) is an early-stage chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy currently in the discovery phase. Developed by Atigen-Cell and Tissue Center (a subsidiary or affiliate of NKGen Biotech), the program focuses on modifying NK cells to express synthetic receptors that direct the cells to recognize and eliminate specific tumor antigens. This modality aims to combine the innate anti-tumor activity of NK cells with the precision of CAR targeting, potentially offering an "off-the-shelf" allogeneic treatment option with a more favorable safety profile regarding cytokine release syndrome (CRS) and graft-versus-host disease (GvHD) compared to traditional CAR-T cell therapies. As of the current reporting, the specific molecular targets and intended cancer indications for this program have not been publicly disclosed.
- Other names
- CAR-NK cell therapygene-engineered NK cell therapy
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on CAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-NK.